Fault or Favoritism? Jannik Sinner’s Doping Case
- Junaidi Saraswati
Tennis is a sport where there is a feeling that authorities pander to the top players. Is Jannik Sinner’s doping case the last evidence?
If you’re a passionate tennis follower like us, you probably know all the players, watch every competition, and have even placed bets with the top Asian and European bookmakers. So, you must have been as shocked as we were when we heard about Sinner’s doping case. On August 20, mere hours after he lifted the title at the Cincinnati Masters and announced himself as one of the favorites for the US Open, news broke about Jannik Sinner. Specifically, the 23-year-old World No. 1 from Italy, had failed two doping tests in March. What’s more, Sinner avoided a ban by claiming the positive results were due to contamination.
This case, unknown before the breaking news, now dominates the narrative at the sport’s top. First, let’s start with what Jannik Sinner tested positive for.
Jannik Sinner's Doping Case Baseline
During the Masters 1000 tournament in Indian Wells, Sinner, who reached the semifinals, underwent an in-competition test conducted by the International Tennis Integrity Agency (ITIA) on March 10, 2024. The test revealed an “adverse analytical finding” (AAF) for Clostebol, a banned anabolic steroid. A subsequent out-of-competition test on March 18 also detected the same substance.
The initial test showed a concentration of 76 picograms (pg) per milliliter. The second test recorded 86 pg per milliliter. Considering that one picogram is equivalent to one trillionth of a gram, the detected amount in Sinner’s bloodstream was minuscule.
In tennis, testing positive for non-specified substances listed by the World Anti-Doping Agency (WADA), such as Clostebol, results in a mandatory provisional suspension. According to the ITIA’s decision, the standard penalty for such violations is a four-year suspension. This seems straightforward, but how did Sinner escape the ban?
Sinner's Defense Overturns Doping Bans
According to ITIA regulations, athletes can appeal provisional suspensions immediately upon notification of a violation. The agency can lift the suspension if the players demonstrate that contamination caused the violation.
Sinner faced suspensions twice. First, from April 4 to April 5 after winning the Miami Masters. Second, between April 17 and April 20 following his semifinal exit at the Monte Carlo Masters. In both instances, Sinner successfully appealed the suspensions. The center of his defense was accidental contamination. His fitness trainer, Umberto Ferrara, had purchased Trofodermin—an over-the-counter spray containing Clostebol—to treat a cut on physiotherapist Giacomo Naldi’s finger. Naldi used the spray daily between March 5 and March 13 while providing massages and sports therapy to Sinner. The tennis player, who suffers from psoriasiform dermatitis, argued that his itchy skin often led to small cuts and sores. He maintained that he was unaware of Ferrara’s possession of Trofodermin or Naldi’s use of it.
The ITIA accepted Sinner’s explanation, leading to the lifting of the provisional suspensions. An independent tribunal appointed by Sport Resolutions later confirmed that Sinner bore “no fault or negligence” for the two violations under the Tennis Anti-Doping Program (TADP) on August 15. Scientific experts supported the credibility of Sinner’s account.
But what exactly is Clostebol?
The Culprit Behind Sinner's Doping Case
Clostebol is an anabolic steroid known for its muscle-building properties and ability to accelerate recovery, enabling athletes to train more intensely. Historically, it was included in the East Germany-sponsored doping program during the late 1960s and 70s.
Although banned in many countries, Clostebol remains common in Italy. For example, in over-the-counter products like Trofodermin. Notably, approximately half of the world’s Clostebol cases, including those involving tennis players, originate from Italy.
Given the prevalence of this drug in Italy and its detection in Sinner’s case, it raises the question: Did he receive preferential treatment in this situation?
Sinner's Doping Clearance Raises Eyebrows
While accidental contamination cases have occurred in the past, the swift clearance of Jannik Sinner has raised concerns about potential double standards. Fellow players, including Denis Shapovalov, Nick Kyrgios, Lucas Pouille, and John McEnroe, have questioned the consistency of the process. The American player Tennys Sandgren added: “This is ridiculous. Second-hand steroids through a massage? ATP always looks out for their money makers”.
Perhaps most telling was the opinion of British player Tara Moore. She pointed out that only top players seem to benefit from favorable opinions by independent tribunals. Moore, who holds a significantly lower ranking, recently returned to her career after a 19-month provisional suspension due to a failed doping test. The ITIA determined that her case was also accidental contamination, absolving her of fault.
In contrast, two-time Grand Slam champion Simona Halep faced a six-year ban recommendation from the ITIA. This was after traces of Roxadustat were found in her sample following a loss at the 2022 US Open. However, Halep successfully appealed to the Court of Arbitration for Sport (CAS), demonstrating that the contamination resulted from a tainted supplement provided by her coaching staff. CAS subsequently reduced her ban to nine months.
The Unequal Playing Field for Tennis's Top Players
The example of Moore and her thoughts get to the core of the reaction to Sinner’s case. His explanations for both suspensions were readily accepted. Also, there was no disclosure of the failed tests until after his exoneration. These outcomes, while adhering to the rules, highlight privileges that may not extend to all players—perhaps influenced by top-tier legal representation. Additionally, the two short-lived suspensions occurred during rare off-weeks in the packed ATP Tour calendar.
Even though the process follows the ITIA protocol, and even though comparing different cases is of little use, it exacerbates suspicions that double standards are rife in tennis. When those feelings alight on doping and sporting integrity, they inevitably catch the light.
The best players get favorable scheduling, receive appearance fees from certain tournaments, and are listened to more closely if they have a gripe about a certain issue. Most players understand and accept this, recognizing that top players have earned their status. Elite players consistently win matches, tournaments, and prize money, making them major attractions for crowds and television networks. Tennis thrives on superstar names, with overall investment and interest in the sport closely linked to their presence.
Sinner's Doping Case and the Future of Tennis Fairness
Despite exoneration, Sinner has still lost the 400 ranking points and the $325,000 prize money he earned at the Indian Wells tournament. Yet, this seems meaningless. Sinner will now play at the U.S. Open, where he will likely be given the most convenient scheduling and all the other privileges the top players are afforded. How his fellow professionals will receive him remains to be seen.
For tennis enthusiasts who follow every twist and turn of the sport, this case highlights the complexities and controversies that can arise. Whether you believe Sinner was treated fairly or see this as a case of favoritism, the debate is sure to continue. As you follow the upcoming matches and perhaps even open a betting account via agent to place your wagers, keep an eye on how Sinner’s doping case unfolds and what it means for the integrity of tennis.
Share:
More Posts
